|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Online Table 3.** Risk ratios (95% confidence intervals) for BPD according to PDA treatment (Y/N) and type of PDA treatment in 19 European regions with low (<15%), medium (15-25%) or high treatment proportions (>25%). Very preterm infants (born at ≤31 weeks of gestation) surviving to 36 weeks of postmenstrual age having complete BPD data (N=6,262). | | | | | | |
|  | **Low PDA treatment proportion**  **N=2,645** | | **Medium PDA treatment proportion**  **N=3,087** | | **High PDA treatment proportion**  **N=530** | |
| **Model 11** | **Model 22** | **Model 11** | **Model 22** | **Model 11** | **Model 22** |
| **PDA-treatment** |  |  |  |  |  |  |
| No PDA treatment | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Any PDA treatment | 1.50 (1.19-1.88) | 1.34 (1.07-1.68) | 1.84 (1.38-2.46) | 1.67 (1.29-2.17) | 2.71 (1.60-4.60) | 2.54 (1.53-4.23) |
| **By type of PDA treatment** |  |  |  |  |  |  |
| No PDA treatment | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Pharmacological treatment only | 1.41 (1.09-1.82) | 1.30 (0.97-1.73) | 1.63 (1.22-2.18) | 1.57 (1.20-2.05) | 2.54 (1.48-4.38) | 2.51 (1.48-4.26) |
| PDA surgery after pharmacological treatment | 1.63 (1.00-2.65) | 1.32 (0.85-2.04) | 2.57 (1.76-3.74) | 1.93 (1.37-2.72) | 3.73 (1.69-8.22) | 2.69 (1.22-5.93) |
| PDA surgery without prior pharmacological treatment | 1.97 (1.51-2.56) | 1.67 (1.18-2.37) | 2.90 (1.76-4.77) | 2.20 (1.46-3.32) | 3.79 (1.62-8.89) | 2.84 (2.13-3.79) |

BPD= bronchopulmonary dysplasia; PDA=patent ductus arteriosus

1 Results from a generalized linear mixed model adjusted for propensity score for PDA treatment. The propensity score for PDA treatment, i.e., a single index variable summarizing the pre-treatment perinatal characteristics, was estimated from presence of preeclampsia/eclampsia, spontaneous onset of labor, preterm premature rupture of membranes (pPROM), maternal infection as indication for delivery, antenatal corticosteroid treatment, mode of delivery, gestational age, birth weight, infant sex, small for gestational age and use of mechanical ventilation on first day of life.

2Model 2: Additional adjustment for duration of mechanical ventilation and number of confirmed neonatal septicemias.

3Intra-ventricular hemorrhage (IVH) grade≥3, cystic periventricular leukomalacia (cPVL), retinopathy of prematurity (ROP) stage ≥3, surgical NEC.